Group 1 - The core point of the article is that *ST Shuangcheng (002693.SZ) has received FDA approval for its injectable bortezomib ANDA product [1] Group 2 - The company announced the FDA approval on its investor interaction platform [1]

Core Viewpoint - The company *ST Shuangcheng has received FDA approval for its injectable bortezomib ANDA, indicating a significant milestone for its product in the U.S. market [1] Group 1 - The company confirmed that its injectable bortezomib ANDA has been granted marketing authorization by the U.S. FDA [1] - The announcement regarding the FDA approval was disclosed on December 19, 2025 [1] - The company expressed gratitude for investor interest in its product and ongoing developments [1]